+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

A multicenter phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes

A multicenter phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes

Antimicrobial Agents and ChemoTherapy 42(11): 2996-2999

A randomized, double-blind, clinic-initiated, sequential dose-escalation pilot study was performed to compare the safety and efficacy of single applications of 1, 3, and 5% cidofovir gel with placebo in the treatment of early, lesional, recurrent genital herpes at five Canadian outpatient sites. Ninety-six patients began treatment within 12 h of lesion appearance and were evaluated twice daily until healing of the lesion occurred. Cidofovir gel at all strengths significantly decreased the median time to negative virus culture in a dose-dependent fashion (3.0 days in the placebo group versus 2.2, 1.3, and 1.1 days in the 1, 3, and 5% cidofovir gel treatment groups, respectively; P = 0.02, 0.0001, and 0.0003, respectively). A trend toward a reduction in the median time to complete healing in association with treatment was present, but the differences were not statistically significant (5.0 days in the placebo group versus 4.3, 4.1, and 4.6 days in the 1, 3, and 5% cidofovir gel treatment groups, respectively). Application site reactions occurred in 3, 5, 19, and 22% of the patients in these four groups, respectively. Treatment-associated lesion recrudescence with delayed healing, which is suggestive of local toxicity, was observed in three patients treated with 5% cidofovir gel and one patient treated with 3% cidofovir gel. In summary, single-dose application of cidofovir gel confers a significant antiviral effect on lesions of recurrent genital herpes. Additional studies are warranted to further identify the optimal efficacious dose of cidofovir in association with the maximum gel strength that can be tolerated.

(PDF emailed within 1 workday: $29.90)

Accession: 010070935

Download citation: RISBibTeXText

PMID: 9797239

Related references

Patient-initiated treatment of recurrent genital herpes with oral famciclovir A Canadian, multicenter, placebo -controlled, dose ranging study. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 34(0): 11, 1994

Treatment of advanced metastatic melanoma using single dose murine monoclonal antibody ricin a chain immunotoxin with dose escalation a phase i study. Proceedings of the American Association for Cancer Research Annual Meeting 30: 288, 1989

Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. International Journal of Radiation Oncology, Biology, Physics 99(4): 797-804, 2017

Open-Label, Dose-Escalation, Phase 1 Study of Safety and Single and Multiple-Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers. Clinical Pharmacology in Drug Development, 2018

Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. Journal of Aerosol Medicine and Pulmonary Drug Delivery 28(2): 106-115, 2016

Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study. International Journal of Clinical Pharmacology and Therapeutics 51(12): 911-923, 2014

Interstitial pulsed-dose-rate brachytherapy alone for low-risk prostate cancer first experiences of a dose escalation single institution prospective phase II study. BrachyTherapy 7(2): 188-189, 2008

A Phase IB Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study of ICA-17043 in Patients with Sickle Cell Disease. Blood 100(11): Abstract No 1761, November 16, 2002

A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecologic Oncology, 2018

Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer. Clinical Lung Cancer 8(2): 135-139, 2006

High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study. European Journal of Cancer & Clinical Oncology 23(9): 1391-1397, 1987

High dose carboplatin in the treatment of lung cancer and mesotherlioma: a phase I dose escalation study. European Journal of Cancer and Clinical Oncology 23(9): 1391-1397, 1987

Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Clinical Cancer Research 8(11): 3401-3406, 2002

Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 15(1): 310-316, 1997

Liposomal cisplatin dose escalation for determining the maximum tolerated dose and dose-limiting toxicity: a phase I study. Anticancer Research 30(4): 1317-1321, 2010